DPP-4 inhibitors, including alogliptin, saxagliptin, and vildagliptin, contain a nitrilo (-CN) group, crucial for enzyme inhibition.
This structural motif enhances DPP-4 binding affinity, prolonging GLP-1 activity to improve glycemic control in diabetes.
Other groups listed have different pharmacological roles.